News Headlines Article

An insider’s view of generic-drug pricing
Los Angeles Times

Bob Toomajian worked for 16 years as Kaiser Permanente’s drug purchasing manager for Southern California, giving him an insider’s knowledge of how medications are priced before reaching consumers.

When it comes to patented name-brand drugs, he told me, pharmaceutical companies try to get away with the highest prices possible. On the other hand, they’re typically recovering millions of dollars in research and development costs, so those sky-high prices are perhaps understandable.

Commands